158 related articles for article (PubMed ID: 23599374)
1. Proteomic identification of neoadjuvant chemotherapy-related proteins in bulky stage IB-IIA squamous cervical cancer.
Zou S; Shen Q; Hua Y; Jiang W; Zhang W; Zhu X
Reprod Sci; 2013 Nov; 20(11):1356-64. PubMed ID: 23599374
[TBL] [Abstract][Full Text] [Related]
2. Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer.
Guo L; Zhang C; Zhu J; Yang Y; Lan J; Su G; Xie X
Life Sci; 2016 Apr; 151():102-108. PubMed ID: 26947588
[TBL] [Abstract][Full Text] [Related]
3. Identification of cervical cancer proteins associated with treatment with paclitaxel and cisplatin in patients.
Liu H; Han Y; Mi R; Zhang Y; Su G; Wang H; Zhou X; Liu X; Zhu B
Int J Gynecol Cancer; 2011 Nov; 21(8):1452-7. PubMed ID: 22027750
[TBL] [Abstract][Full Text] [Related]
4. Proteomic identification of differentially-expressed proteins in squamous cervical cancer.
Zhu X; Lv J; Yu L; Zhu X; Wu J; Zou S; Jiang S
Gynecol Oncol; 2009 Jan; 112(1):248-56. PubMed ID: 19007971
[TBL] [Abstract][Full Text] [Related]
5. Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT.
Zhu H; Tao X; Zhou L; Sheng B; Zhu X; Zhu X
BMC Cancer; 2019 Aug; 19(1):865. PubMed ID: 31470801
[TBL] [Abstract][Full Text] [Related]
6. Candidates for tumor markers of cervical cancer discovered by proteomic analysis.
Song JY; Bae HS; Koo do H; Lee JK; Jung HH; Lee KW; Lee NW
J Korean Med Sci; 2012 Dec; 27(12):1479-85. PubMed ID: 23255846
[TBL] [Abstract][Full Text] [Related]
7. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma.
Zhu H; Pei HP; Zeng S; Chen J; Shen LF; Zhong MZ; Yao RJ; Shen H
J Proteome Res; 2009 Aug; 8(8):3969-76. PubMed ID: 19507834
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study.
Qin T; Zhen J; Zhou M; Wu H; Ren R; Qu B; Wang H
Int J Surg; 2016 Jun; 30():121-5. PubMed ID: 27131759
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy.
Jin L; Shen Q; Ding S; Jiang W; Jiang L; Zhu X
Gynecol Oncol; 2012 Jul; 126(1):140-6. PubMed ID: 22487537
[TBL] [Abstract][Full Text] [Related]
10. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.
Choi CH; Song SY; Kang H; Lee YY; Kim CJ; Lee JW; Kim TJ; Kim BG; Lee JH; Bae DS
J Obstet Gynaecol Res; 2010 Apr; 36(2):304-10. PubMed ID: 20492381
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stage Ib2 and IIa cervical squamous cell cancer patients.
Liang Y; Lü B; Chen X; Qin J; Cheng X; Xie X; Lü W
Virchows Arch; 2016 Mar; 468(3):329-36. PubMed ID: 26637198
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.
Choi CH; Song SY; Choi JJ; Park YA; Kang H; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
BMC Cancer; 2008 Oct; 8():295. PubMed ID: 18847499
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
15. Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis.
Zhu X; Ding M; Yu ML; Feng MX; Tan LJ; Zhao FK
BMC Cancer; 2010 Jun; 10():290. PubMed ID: 20546628
[TBL] [Abstract][Full Text] [Related]
16. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis.
Guo X; Hao Y; Kamilijiang M; Hasimu A; Yuan J; Wu G; Reyimu H; Kadeer N; Abudula A
Tumour Biol; 2015 Mar; 36(3):1711-20. PubMed ID: 25427637
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of bulky stage IB and IA cervical cancer patients treated by radical hysterectomy with and without neoadjuvant chemotherapy: long-term follow-up.
Manusirivithaya S; Chareoniam V; Pantusart A; Isariyodom P; Srisomboon J
J Med Assoc Thai; 2001 Nov; 84(11):1550-7. PubMed ID: 11853297
[TBL] [Abstract][Full Text] [Related]
18. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics.
Wang W; Jia HL; Huang JM; Liang YC; Tan H; Geng HZ; Guo LY; Yao SZ
Br J Cancer; 2014 Apr; 110(7):1748-58. PubMed ID: 24569473
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (>/=4 cm) stage IB and IIA cervical carcinoma.
Huang HJ; Chang TC; Hong JH; Tseng CJ; Chou HH; Huang KG; Lai CH
Int J Gynecol Cancer; 2003; 13(2):204-11. PubMed ID: 12657125
[TBL] [Abstract][Full Text] [Related]
20. Protein expression patterns in primary carcinoma of the vagina.
Hellman K; Alaiya AA; Schedvins K; Steinberg W; Hellström AC; Auer G
Br J Cancer; 2004 Jul; 91(2):319-26. PubMed ID: 15199389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
